Powder: -20°C for 3 years | In solvent: -80°C for 1 year
J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.
Description | J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity. |
Targets&IC50 | HDAC6:4.7 nM |
In vitro | J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance. J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner. |
In vivo | J22352 is well tolerated in mice.J22352 (10?mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. |
Molecular Weight | 415.44 |
Formula | C24H21N3O4 |
CAS No. | 2252395-44-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (300.89 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
J22352 2252395-44-9 Apoptosis Proteases/Proteasome Caspase J-22352 J 22352 inhibitor inhibit